Skip to main content
. 2020 Aug 14;26(30):4428–4441. doi: 10.3748/wjg.v26.i30.4428

Table 5.

Colectomy at 12 mo of vedolizumab therapy

Colectomy, n Australia Oxford P value
19/210 13/93 0.25
Colectomy, n Anti-TNF naive Anti-TNF exposed P value
9/182 23/121 0.0005
Colectomy, n Primary LOS Secondary LOS P value
10/45 23/61 0.795

VDZ: Vedolizumab; TNF: Tumor necrosis factor; Primary LOR: Primary loss of response; Secondary LOR: Secondary loss of response.